Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus OGESTREL 0 5 50 21.
BLISOVI FE 1/20 vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive